The Board of Directors of Jiangsu Hengrui Medicine Co., Ltd. has authorized a buyback plan on March 13, 2022.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
46.18 CNY | +1.25% | +10.32% | +2.10% |
04-26 | Hengrui Pharma Gets Nod to Trial Insulin Aspart Injection; Shares Up 3% | MT |
04-17 | Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.10% | 40.02B | |
+26.47% | 661B | |
+26.74% | 566B | |
-6.33% | 352B | |
+19.35% | 332B | |
+4.23% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.04% | 145B |
- Stock Market
- Equities
- 600276 Stock
- News Jiangsu Hengrui Medicine Co., Ltd.
- Jiangsu Hengrui Medicine Co., Ltd. authorizes a Buyback Plan.